Get the Stockscreener App
4.13
6.17%
0.24
After Hours:
4.13
Mannkind Corp stock is traded at $4.13, with a volume of 9.44M.
It is up +6.17% in the last 24 hours and up +7.55% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
See More
Previous Close:
$3.89
Open:
$4.06
24h Volume:
9.44M
Relative Volume:
1.66
Market Cap:
$1.28B
Revenue:
$360.78M
Net Income/Loss:
$-23.91M
P/E Ratio:
-52.88
EPS:
-0.0781
Net Cash Flow:
$13.07M
1W Performance:
+2.48%
1M Performance:
+7.55%
6M Performance:
-24.36%
1Y Performance:
+1.23%
1-Day Range:
$3.98
$4.23
1-Week Range:
$3.7101
$4.23
52-Week Range:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
4.13 | 1.28B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Oct-10-25 | Initiated | Leerink Partners | Outperform |
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MNKD|MannKind Corp|Price:4.130|Chg%:+0.240 - TradingKey
MannKind (MNKD) Stock Looks Undervalued On Cash Flow Yet Mixed On Broader Checks - Yahoo Finance
MannKind Corporation (MNKD) Shares Surge on FDA Approval and $50M Placement - GuruFocus
MannKind Corporation Raises $50 Million in Private Placement Following FDA Approval of Furoscix ReadyFlow - Kalkine Media
MannKind closes $50M financing, wins FDA nod for Furoscix auto-injector - MassDevice
MannKind Corporation (MNKD) stock price, news, quote and history - Yahoo Finance UK
MannKind Announces FDA Approval of Furoscix ReadyFlow, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease - FinanzNachrichten.de
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease - Benzinga
MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Yahoo Finance
MannKind Stock Jumps After FDA Clears Furoscix Auto-Injector, Firm Secures $50 Million PIPE - finance.biggo.com
MannKind Corporation (MNKD) Stock Price, News, Quote & History - Yahoo! Finance Canada
FDA Approves Furosemide Autoinjector for Treatment of Edema in CKD or Heart Failure - Pharmacy Times
H.C. Wainwright reiterates Buy on MannKind stock ahead of PDUFA - Investing.com
MannKind shares surge after FDA approves Furoscix ReadyFlow and company secures $50 million financing - Yahoo Finance
H.C. Wainwright reiterates Buy on MannKind stock ahead of PDUFA By Investing.com - Investing.com Canada
MNKD Stock Rises Premarket As FDA Verdict Nears – Retail Optimism Builds - Stocktwits
Why is MannKind stock rallying today? - Investing.com
MannKind raises $50 million in private placement led by Frazier - Investing.com
MannKind stock jumps 6% on FDA approval, $50M financing - Investing.com
At-home autoinjector delivers IV-equivalent therapy in under 10 seconds - Stock Titan
MannKind (MNKD) Set for Potential Growth Ahead of FDA Decision - GuruFocus
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Form 4 MannKind Corp For: 21 July By Investing.com - Investing.com South Africa
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
MannKind EVP David Thomson sells $97,641 in MNKD shares on July 17 - Investing.com India
Form 4 MannKind Corp For: 21 July - Investing.com India
MNKD Stock Price, Quote & Chart - ChartMill
MannKind Executive Sells 123,000 Shares Amid Performance Concerns - Intellectia AI
What This MannKind Filing Reveals About Three Years of Underperformance - Yahoo Finance
What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million - Yahoo Finance
Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk - Yahoo Finance
Form 4 MannKind Corp For: 20 July By Investing.com - Investing.com Nigeria
MannKind CEO Sells Shares to Cover Tax Liabilities - Intellectia AI
Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares? - Yahoo Finance
MannKind EVP David Thomson sells $97,641 in company stock - Investing.com UK
MannKind director Steven Binder sells $213,089 in company stock By Investing.com - Investing.com India
MannKind EVP David Thomson sells $97,641 in company stock By Investing.com - Investing.com South Africa
Form 4 MannKind Corp For: 17 July By Investing.com - Investing.com South Africa
MannKind Corp (MNKD) EVP receives 70,550 shares from performance RSUs - Stock Titan
MannKind (MNKD) CEO vests 350,260 shares, withholds stock for taxes - Stock Titan
MannKind director Steven Binder sells $213,089 in company stock - Investing.com
MannKind (MNKD) insider schedules 24,109-share sale and reports new RSU, PSU awards - Stock Titan
Planned sale of 52,485 MNKD shares disclosed by MNKD (NASDAQ: MNKD) - Stock Titan
MannKind Corporation (MNKD) Up 20% Since Afrezza FDA Approval - Yahoo Finance
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mannkind Corp Stock (MNKD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Castagna Michael | Chief Executive Officer |
Jul 15 '26 |
Option Exercise |
0.00 |
350,260 |
0 |
2,796,979 |
| Singh Sanjay R | EVP Technical Operations |
Jul 15 '26 |
Option Exercise |
0.00 |
70,550 |
0 |
525,761 |
| Thomson David | EVP Genl Counsel & Secretary |
Jul 15 '26 |
Option Exercise |
0.00 |
93,790 |
0 |
920,089 |
| Thomson David | EVP Genl Counsel & Secretary |
Jul 17 '26 |
Sale |
4.05 |
24,109 |
97,641 |
797,554 |
| Binder Steven B. | Director |
Jul 15 '26 |
Option Exercise |
0.00 |
93,790 |
0 |
901,798 |
| Binder Steven B. | Director |
Jul 17 '26 |
Sale |
4.06 |
52,485 |
213,089 |
824,918 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):